Reaction

Dysaesthesia reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,986 reports · 94 co-occurring drugs

As of the last recalculation, Dysaesthesia appears in 2,986 FAERS reports alongside 94 co-occurring drug terms. The strongest observed disproportionality signal is BLEOMYCIN SULFATE (PRR 23.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Bleomycin Sulfate	35	23.9	24.0
Doxepin	31	21.5	21.6
Doxepin Hydrochloride	36	20.1	20.2
Oxaliplatin	142	14.0	14.0
Granisetron Hydrochloride	17	11.4	11.4
Fondaparinux Sodium	11	9.5	9.5
Paclitaxel (Aibumin-Bound)	102	8.9	8.9
Paclitaxel	117	8.5	8.5
Ciprofolxacin	81	8.1	8.1
Ciprofloxacin Tablets	81	8.1	8.1
Baclofen	96	8.0	8.0
Fingolimod Hcl	91	7.5	7.5
Pertuzumab	29	7.5	7.5
Bupivacaine	10	7.5	7.5
Clotrimazole	13	7.4	7.4
Drs. Clotrimazole	12	7.3	7.3
Family Wellness Clotrimazole	12	7.3	7.3
Clotrimazole Topical	12	7.3	7.3
Capecitabine	92	7.2	7.2
Ciprofloxacin	92	7.2	7.2
Trimethoprim	12	7.1	7.1
Ciprofloxacin Hydrochloride	96	7.1	7.1
Gentamicin	13	7.0	7.0
Rifampicin	10	6.9	6.9
Methylprednisolone Sodium Succinate	45	6.8	6.9
Granisetron	10	6.7	6.7
Ritonavir 100 Mg	14	6.6	6.6
Leucovorin Calcium	17	6.2	6.2
Fluorouracil Cream, 0.5%	66	6.1	6.2
Fluorouracil	66	6.1	6.1
Pregabalin	221	6.0	6.0
Acetylcysteine	8	5.9	5.9
Ado-Trastuzumab Emtansine	7	5.8	5.8
Gentamicin Sulfate	13	5.8	5.8
Gemcitabine Hydrochloride	43	5.7	5.7
Gemcitabine	32	5.7	5.7
Zonisamide	12	5.7	5.7
Pemetrexed	17	5.6	5.6
Diazepam Oral Solution (Concentrate)	69	5.5	5.5
Diazepam Oral	69	5.5	5.5
Trastuzumab	53	5.5	5.5
Mirtazapine	70	5.4	5.4
Ritonavir	22	5.3	5.3
Pyrazinamide	7	5.2	5.2
Letrozole Tablets	35	5.1	5.1
Diclofenac	62	5.1	5.1
Letrozole	44	5.0	5.0
Docetaxel Anhydrous	48	5.0	5.0
Docetaxel	48	5.0	5.0
Metoclopramide Hydrochloride	54	4.9	5.0
Valsartan Oral	38	4.9	4.9
Exemestane	15	4.9	4.9
Irinotecan Hydrochloride	9	4.9	4.9
Metoclopramide	38	4.9	4.9
Ocrelizumab	42	4.8	4.8
Brentuximab Vedotin	7	4.8	4.8
Doxorubicin	59	4.7	4.7
Umeclidinium	6	4.7	4.7
Enoxaparin Sodium	38	4.7	4.7
Etoposide	47	4.5	4.5
Lapatinib	10	4.5	4.5
Thalidomide	23	4.4	4.4
Carboplatin	78	4.4	4.4
Eplerenone	8	4.4	4.4
Ifosfamide	13	4.2	4.2
Lamivudine	18	4.1	4.1
Doxorubicin Hydrochloride	19	4.1	4.1
Vemurafenib	7	4.1	4.1
Fosaprepitant Dimeglumine	8	4.1	4.1
Pemetrexed Disodium	22	4.0	4.0
Cefepime	8	3.9	3.9
Lamivudine Oral	14	3.9	3.9
Aprepitant	10	3.8	3.8
Bevacizumab	64	3.7	3.7
Cladribine	5	3.6	3.6
Teriflunomide	23	3.6	3.6
Atazanavir	7	3.4	3.4
Rotigotine	7	3.4	3.4
Interferon Beta-1B	9	3.3	3.3
Tapentadol Hydrochloride	14	2.9	2.9
Thiotepa	4	2.9	2.9
Ranitidine Hydrochloride	22	2.8	2.8
Sunitinib Malate	15	2.7	2.7
Ravulizumab	5	2.6	2.6
Glatiramer Acetate	22	2.6	2.6
Iohexol	3	2.5	2.5
Pembrolizumab	36	2.4	2.4
Pegfilgrastim	33	2.3	2.3
Tirzepatide	51	2.2	2.2
Ofatumumab	10	2.1	2.1
Trifluridine And Tipiracil	3	2.0	2.0
Ixazomib	8	1.9	1.9
Dalfampridine	19	1.9	1.9
Palbociclib	24	1.8	1.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.